Can-Fite BioPharma Ltd. (CANF)
- Previous Close
1.9200 - Open
2.0000 - Bid 1.9100 x 1100
- Ask 2.0200 x 1000
- Day's Range
1.9100 - 2.0000 - 52 Week Range
1.7100 - 3.3300 - Volume
8,664 - Avg. Volume
19,984 - Market Cap (intraday)
9.881M - Beta (5Y Monthly) 0.91
- PE Ratio (TTM)
-- - EPS (TTM)
-3.0000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.00
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.
www.canfite.comRecent News: CANF
Performance Overview: CANF
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CANF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CANF
Valuation Measures
Market Cap
10.22M
Enterprise Value
1.34M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.36
Price/Book (mrq)
1.58
Enterprise Value/Revenue
1.81
Enterprise Value/EBITDA
-0.16
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-53.15%
Return on Equity (ttm)
-142.49%
Revenue (ttm)
743k
Net Income Avi to Common (ttm)
-7.63M
Diluted EPS (ttm)
-3.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
8.92M
Total Debt/Equity (mrq)
0.64%
Levered Free Cash Flow (ttm)
-5.12M